Antivascular Endothelial Growth Factor Monotherapy for Choroidal Neovascularization Associated With Retinochoroidal Coloboma: Case Series.

摘要: PURPOSE This study aimed to report the outcomes of antivascular endothelial growth factor (anti-VEGF) monotherapy for choroidal neovascularization (CNVM) associated with retinochoroidal coloboma (RCC). DESIGN A retrospective case series. METHODS was a series 3 eyes CNVM RCC that presented LV Prasad Eye Institute, Hyderabad, India, between January 2006 and 2014. Reported data included demographics, preoperative details (symptoms, duration symptoms, visual acuity), treatment methods, postoperative (visual acuity, follow-up, recurrence). These were compared 9 other cases previously reported in literature. RESULTS Three patients (2 females 1 male) included, mean age 18.3 years (range, 2-32 years). The best corrected acuity ranged from 20/540 20/100. All treated intravitreal bevacizumab injections. number injections 2.0 1-3) follow-up 12 months 4-24 months) no recurrence. at last improved, ranging 20/310 20/60. CONCLUSIONS In view good recurrence lesser injections, anti-VEGF could be considered as coloboma-associated CNVM.